![]() |
|
|
Vol. 57, Issue 6, 1218-1223, June 2000
Departments of Physiology and Biophysics (H.-S.W., I.S.C) and Neurobiology and Behavior (D.M.), Institute of Molecular Cardiology, State University of New York, Stony Brook, New York; and Central Nervous System Diseases Research, DuPont Pharmaceuticals, Wilmington, Delaware (B.S.B.)
| |
Abstract |
|---|
|
|
|---|
Channels formed by coassembly of the KCNQ1 (KvLQT1) subunit and the minK subunit underlie slowly activating cardiac delayed rectifier (IKs) in the heart, whereas two other members of the KCNQ channel family, KCNQ2 and KCNQ3, coassemble to underlie the M current in the nervous system. Because of their important physiological function, KCNQ channels have potential as drug targets, and an understanding of possible mechanisms that would enable tissue-specific targeting of these channels will be of significant value to drug development. In this study, we examined the role of the minK subunit in determining the response of KCNQ1 channels to blockade by the cognitive enhancer XE991. Coexpression with minK markedly decreased the sensitivity of KCNQ1 to blockade by XE991. When measured at the end of a 500-ms step, XE991 blockade of the KCNQ1+minK current had a KD value of 11.1 ± 1.8 µM, approximately 14-fold less sensitive than the block of the KCNQ1 current (KD = 0.78 ± 0.05 µM). In addition, XE991 reduced activation and deactivation time constants and caused a rightward shift in the activation curve of KCNQ1+minK, but affected none of these parameters for KCNQ1 alone. Also, XE991 block of KCNQ1+minK, but not of KCNQ1, was time- and voltage-dependent. We conclude that the presence of minK in the IKs channel complex gives rise to differential sensitivity of KCNQ and IKs channels to blockade by XE991. Our results have implications for drug development by demonstrating the important potential role of accessory subunits in determining the pharmacological properties of KCNQ channels.
| |
Introduction |
|---|
|
|
|---|
The
KCNQ potassium channels have recently emerged as a family of channels
with important physiological functions. Members of the family
contribute to several key potassium currents in the heart and nervous
system, and mutations in the KCNQ genes are closely related
to several human genetic diseases. In coassembly with the minK (KCNE1)
accessory subunit, the KCNQ1 (KvLQT1) channel subunit underlies the
cardiac slowly activating cardiac delayed rectifier
(IKs) current (Barhanin et al., 1996
; Sanguinetti
et al., 1996
), a slowly activating and deactivating
delayed-rectifier potassium current that contributes to the
repolarization of the cardiac action potential. Mutations in the
KCNQ1 (KvLQT1) gene cause delayed cardiac action
potential repolarization and a prolonged QT interval in the ECG,
resulting in a congenital cardiac disorder known as long QT syndrome
that can lead to ventricular arrhythmias and sudden death (Wang et al.,
1996
). Two new members of the KCNQ family, KCNQ2 and KCNQ3, have been
recently identified (Biervert et al., 1998
; Charlier et al., 1998
;
Singh et al., 1998
). Unlike KCNQ1, which is predominantly a cardiac
channel, these two channels are present exclusively in the nervous
system. We have shown previously that the KCNQ2 and KCNQ3 channel
subunits coassemble to form heteromultimers that underlie the M current
(Wang et al., 1998
), a voltage-gated potassium current that plays a
critical role in regulating neuronal excitability in the nervous system
(Brown, 1988
; Yamada et al., 1989
; Wang and McKinnon, 1995
).
Because of their important physiological functions, KCNQ channels have
clear potentials as drug targets. In particular, the potentials of the
neuronal KCNQ channels as drug targets are demonstrated by the recent
development of a class of chemical compounds represented by linopirdine
and the newer analog XE991. These compounds are potent blockers of
cloned KCNQ channels (Wang et al., 1998
) and the native M current in a
variety of neurons (Costa and Brown, 1997
; Lamas et al., 1997
; Schnee
and Brown, 1998
; Wang et al., 1998
). These compounds have been shown to
have cognitive enhancing effects, and they act by increasing the
stimulus-evoked release of a number of neurotransmitters in the central
nervous system (Aiken et al., 1996
; Zaczek et al., 1998
). It has been
suggested that blockade of the M channel underlies, at least in part,
the enhancement of transmitter release by these drugs (Kristufek et al., 1999
).
However, because the KCNQ channels have generally similar
pharmacological profiles, a potential problem in the development of
drugs that target neuronal KCNQ channels is that the cardiac KCNQ1
(KvLQT1) channel, which together with the minK subunit underlies the
native IKs, may also be affected. The need for
neuronal specificity is underscored by the finding that adverse
blockade of IKs can prolong cardiac action
potential duration and cause acquired forms of long QT syndrome (Roden
and George, 1996
). In this study, we tested the role of the minK
accessory subunit in determining the sensitivity of
IKs channels to these cognitive enhancing drugs. Using the blockade by the cognitive enhancer XE991 as a case study, we
have shown that incorporation of the minK regulatory subunit in
IKs channels confers a lower sensitivity of the
channel complex to XE991, providing a molecular basis for the
differential sensitivity of KCNQ and IKs channels
to XE991.
| |
Materials and Methods |
|---|
|
|
|---|
Preparation of KCNQ1 and minK cRNA.
The human KCNQ1 cDNA (a
generous gift from Dr. M. T. Keating, University of Utah; Wang et
al., 1996
) was linearized with EcoRI, and cRNA was
transcribed using SP6 RNA polymerase. The minK cDNA (originally
obtained from Dr. S. Nakanishi, Kyoto University, Japan; Takumi et al.,
1988
) was linearized with NotI, and cRNA was transcribed
using T7 RNA polymerase.
Expression in Xenopus Oocytes.
Oocytes were
prepared from mature female Xenopus laevis as described
previously (Wang et al., 1997
). Frogs were anesthetized in ice water
containing 0.1% solution of Tricaine. Defolliculation was performed by
incubation for 2 h in 2 mg/ml collagenase (type VIII, Sigma, St.
Louis, MO) in Ca2+-free OR2 oocyte medium with
gentle agitation. Oocytes were stored in OR3 solution [50% L-15
medium (Life Technologies, Gaithersburg, MD), 1 mM glutamine, 15 mM
Na-HEPES (pH 7.6), 0.1 mg/ml gentamicin] at 18°C. Oocytes were
injected with 35 ng of KCNQ1 cRNA or a 50:1 ratio of KCNQ1 and minK
cRNAs (17.5 and 0.35 ng, respectively) using a microdispenser and a
micropipette with tip diameter of 10 to 15 µm. Injected oocytes were
incubated at 18°C for 24 to 48 h before analysis.
. The standard
extracellular recording solution (OR2 solution) contained 85 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM
MgCl2, and 5 mM Na-HEPES (pH 7.6). Data
collection and analysis were performed using pCLAMP software (Axon
Instruments, Foster City, CA). XE991 was obtained from DuPont
Pharmaceuticals (Wilmington, DE) and dissolved in 0.1 N HCl as a 10-mM
stock solution.
Data Analysis. Group data are presented as mean ± S.E. Statistical tests of drug effects were performed using paired, two-tail Student's t tests unless otherwise indicated. A t value giving P < .05 was considered to be significant.
| |
Results |
|---|
|
|
|---|
To test the hypothesis that the minK accessory subunit modulates
the effect of XE991 on IKs channels,
voltage-clamp recordings were made from Xenopus oocytes
injected with KCNQ1 cRNA alone or with KCNQ1 and minK cRNAs in a 50:1
weight ratio. The basic biophysical properties of the expressed KCNQ1
and KCNQ1+minK channels were similar to those described previously
(Barhanin et al., 1996
; Sanguinetti et al., 1996
) (Fig.
1A). The KCNQ1 current is a delayed rectifier that activates relatively rapidly and exhibits weak rectification at positive voltages caused by rapid inactivation. Deactivation of the current at
50 mV was slow and preceded by an
initial phase of recovery from inactivation. Coexpression of minK with
KCNQ1 channels resulted in a current with considerably slower
activation and deactivation kinetics than those of the KCNQ1 channels
alone. Activation of the KCNQ1+minK channel was sigmoidal and did not
reach steady state even during prolonged depolarizing voltage steps.
|
The native IKs in cardiac myocytes has slow
activation kinetics and is activated toward the end of the plateau
phase of cardiac action potentials, which are typically several hundred
milliseconds in duration in human. For this reason, a relatively short
(500 ms) depolarizing step to 0 mV was initially used to test the
sensitivity of the KCNQ1 and KCNQ1+minK (IKs)
channels to XE991. Bath application of 3 µM XE991 significantly
reduced the KCNQ1 current amplitude (Fig. 1B), consistent with the
previously described high sensitivity of KCNQ channels to blockade by
XE991 (Wang et al., 1998
). In contrast, the effect of the same
concentration of XE991 on the KCNQ1+minK current was markedly smaller.
When measured at the end of the 500-ms step, XE991 blockade of the
KCNQ1+minK current has a KD value of
11.1 ± 1.8 µM (n = 7), which is greater than 14-fold less sensitive than the block of the KCNQ1 current
(KD = 0.78 ± 0.05 µM,
n = 6; Fig. 1C). By comparison, the
KD values for XE991 block of KCNQ2 and
KCNQ2+KCNQ3 channels are 0.7 and 0.6 µM, respectively (Wang et al.,
1998
).
The dose-dependent block of the KCNQ1+minK current by XE991 was
characterized further using a 4-s depolarizing step (Fig. 2A). The longer step revealed that the
blockade of the current is strongly time-dependent, with the percentage
of blockade increasing over time, as shown in Fig. 2B. The time
dependence of XE991 blockade of KCNQ1+minK is also reflected in the
KD-step duration relationship (Fig. 2C), in
which the KD value decreases from 13.3 ± 1.9 µM at 300 ms to 8.4 ± 1.3 µM at 1 s to 5.0 ± 0.8 µM at 4 s (n = 7). In marked contrast,
the KD value for block of the KCNQ1 current has little time dependence (0.76 ± 0.06 µM at 200 ms and
0.84 ± 0.08 µM at 2 s; n = 6) and is
significantly lower than that of the KCNQ1+minK current at all time
points tested (Fig. 2, C and D).
|
One possibility is that the XE991 sensitivity of the two channels appeared different because KCNQ1+minK activates extremely slowly, and the drug blockade is not at steady state for the time period tested. Indeed, the KD-time curve for the KCNQ1+minK current shown in Fig. 2C apparently had not reached steady state at 4 s. To test this hypothesis, a prolonged 40-s step was used. At the end of the depolarizing step, the blockade of KCNQ1+minK by XE991 was close to steady state, and the KD value was estimated to be 3.9 ± 0.4 µM (n = 3; data not shown), not significantly lower than that observed at 4 s. This suggests that the lower XE991 sensitivity of the KCNQ1+minK channel is probably not simply attributable to the slow kinetics of the channel activation and blockade.
The time dependence of the XE991 block of the KCNQ1+minK current is
possibly attributable to a change in activation kinetics of the current
in the presence of the drug. Application of XE991 significantly
increased both the rate of activation and deactivation of the
KCNQ1+minK current as shown in Fig. 3A,
in which the outward and tail currents in the presence of 3 µM XE991
were normalized to those in control. The effect of XE991 is
dose-dependent (Fig. 3B). Activation of KCNQ1+minK can be described by
the second power of a single exponential function, and the time
constant was 1.28 ± 0.20 s in control and was decreased to
0.94 ± 0.18 s and 0.84 ± 0.15 s in the presence
of 3 and 10 µM XE991, respectively (P < .01, n = 4). For deactivation of the current, which can be
approximated by a single exponential, the time constant was 1.64 ± 0.32 s in control and was decreased to 1.04 ± 0.22 s
and 0.84 ± 0.17 s in the presence of 3 and 10 µM XE991,
respectively (P < .05, n = 4). In
contrast, the effect of XE991 on the kinetics of the KCNQ1 current was
much smaller (Fig. 3C). Activation of the KCNQ1 current is biphasic,
and to simplify data analysis and presentation, the half-rise time for
2-s depolarizing steps was used as a measurement of the activation
rate. Application of 1 and 3 µM XE991 did not cause any significant
change in the average half-rise time of activation and the time
constant of deactivation of the KCNQ1 current (P > .5;
Fig. 3D).
|
Association with the minK subunit altered the voltage dependence of the
block of the KCNQ1 channel by XE991. Figure
4A shows the
KD values for XE991 block measured at the
end of 2-s depolarizing steps to various voltages. The blockade of
KCNQ1 current by XE991 is essentially voltage-independent for the
voltage range tested, whereas the blockade of the KCNQ1+minK current
shows a weak voltage dependence, with a lower affinity at positive
voltages. We also examined the effect of XE991 on the activation curves
of the KCNQ1 and KCNQ1+minK current. Coexpression with minK shifted the
average midpoint for the conductance-voltage curve of the KCNQ1 channel to a more positive potential by 18.3 mV and decreased the slope factor
by 2 mV (Fig. 4B), similar to previously described results (Sanguinetti
et al., 1996
). Because of the large difference in KCNQ1 and KCNQ1+minK
channels' sensitivity to XE991, a concentration that causes
half-blockade was used for each current. Application of 1 µM XE991
had a small but significant effect on the conductance-voltage curve of
the KCNQ1 current (midpoint,
18.0 ± 0.6 and
19.9 ± 0.3 mV in control and XE991, respectively; P < .01, n = 5; Fig. 4B). In contrast, application of 5 µM
XE991 shifted the midpoint of the isochronal (4 s) activation curve of
the KCNQ1+minK current by 8.6 mV in the positive direction, from
0.3 ± 2.4 mV to 8.9 ± 3.0 mV (P < .05, n = 5; Fig. 4B). This shift was in the direction opposite to that observed for the KCNQ1 channel.
|
Ionic currents in cardiac myocytes, including
IKs, are activated repeatedly by the rhythmic
activity of the heart. Therefore, the use dependence of drug actions
must be investigated in pharmacological studies of cardiac ionic
currents and their molecular clones. For this reason, the effect of
XE991 was tested on the KCNQ1 and KCNQ1+minK currents activated
repetitively at 1 Hz by a 250-ms depolarizing step to 0 mV from a
holding potential of
80 mV, a protocol designed to mimic the
activation of IKs in cardiac myocytes. Some
accumulation of activation of currents was observed, especially for
KCNQ1+minK, which quickly reached steady state. Figure 4C shows
four consecutive superimposed traces in control and in the presence of
3 µM XE991 for the KCNQ1 and KCNQ1+minK currents. The effect of XE991
on the two currents was markedly different and was similar to that
described in Fig. 1B, suggesting that there is little accumulation of
block by XE991 for the KCNQ1+minK channel under these conditions.
| |
Discussion |
|---|
|
|
|---|
The native cardiac IKs channels are formed
by the coassembly of the pore-forming KCNQ1 subunits with the minK
accessory protein. This study tested the hypothesis that KCNQ and
IKs channels have differential sensitivity to the
cognitive enhancer XE991 and has shown that the minK subunit confers
the lower sensitivity of IKs (KCNQ1+minK) to
XE991. When studied using a 500-ms depolarizing step, the KCNQ1+minK
channel was 14- to 18-fold less sensitive to XE991 blockade than were
KCNQ1 and neuronal KCNQ channels (Wang et al., 1998
). Other
characteristics of XE991 blockade of the KCNQ1+minK channels were also
different. XE991 blocks KCNQ1+minK in a voltage- and time-dependent
manner, whereas XE991 blockade of KCNQ1 was primarily voltage- and
time-independent. The activation and deactivation kinetic properties of
the KCNQ1+minK channel, but not those of KCNQ1, were altered
significantly in the presence of XE991. These results suggest that the
minK subunit has an important role in regulating the interaction
between the IKs channel complex and XE991. Such
an effect of the minK subunit may allow the cardiac IKs and neuronal KCNQ channels to be
differentially affected by XE991. Although no published clinical
assessment of XE991 is available, linopirdine, a close analog of XE991,
seems to act in a tissue-specific manner. When evaluated in patients,
linopirdine enhanced neurotransmitter release while causing no
significant adverse changes in cardiac function, including changes in
the ECG (Pieniaszek et al., 1995
; Rockwood et al., 1997
).
Linopirdine blocks the M channel (KCNQ2+KCNQ3) by a direct interaction
with the channel protein rather than through a second messenger-mediated pathway (Costa and Brown, 1997
; Lamas et al., 1997
).
Presumably the closely related compound XE991 blocks the KCNQ1 and
KCNQ1+minK by the same mechanism. As a result of the pronounced time
dependence of the KCNQ1+minK blockade, the difference in affinity for
XE991 of the KCNQ1 and KCNQ1+minK channels is most significant when
examined using relatively short steps and decreases over time. The time
dependence of the KCNQ1+minK blockade can be simply explained by an
open-channel block with a slow on-rate for drug binding. However, such
a mechanism is inconsistent with an increased rate of deactivation of
the channel in the presence of XE991. Also, there is no cumulative
blockade when the current is stimulated repetitively. Although the
analysis of the blockade of the KCNQ1+minK is complicated by the
extremely slow activation rate and the lack of steady-state activation,
we believe that the apparent time dependence of blockade is secondary
to the change in channel gating properties. The mechanism by which
XE991 alters the gating properties of the KCNQ1+minK channel, but not
of KCNQ1, is unknown. It may involve allosteric interactions between
XE991 and the KCNQ1 channel at a site that is modified in the presence of minK.
The modulatory effect of minK on IKs drug
sensitivity reported here is not unique for blockade by XE991. It has
been shown previously that coexpression of minK subunits with KCNQ1
channels decreases the effect of other drugs, including clofilium and a benzodiazepine, R-L3, on the channel (Yang et al., 1997
; Salata et al.,
1998
). Interestingly, it also has been shown that compared with the
KCNQ1 channel, the KCNQ1+minK channel has higher affinity for several
antiarrhythmic drugs (Busch et al., 1997
). Therefore, association with
the minK subunits appears to affect the general pharmacological profile
of the KCNQ1 channel, and these intriguing interactions between minK
and KCNQ1 subunits may make it possible to develop drugs that can
selectively target either the neuronal or cardiac KCNQ channels.
The significance of this study goes beyond the interactions between
KCNQ channels with minK. A previous study has shown that the presence
of the
-1 accessory subunit alters the block of the cardiac sodium
channel by lidocaine (Makielski et al., 1996
). Recently, it was
suggested that MiRP1, a minK-related peptide with one putative
transmembrane domain, coassembles with the HERG potassium
channel to form the rapidly activating cardiac delayed rectifier
channel IKr, and it has been shown that
coexpression with MiRP1 affects the block of the HERG channel by the
methanesulfonanilide E4031 (Abbott et al., 1999
). Taken together, these
findings and our results have implications for drug development by
demonstrating that the pharmacological profile of an ion channel is not
only determined by the properties of the pore-forming
-subunits, but also can be influenced by the accessory or regulatory subunits with
which the
-subunits coassemble. As a case study, our results also
show that the tissue specificity of drugs can be achieved by taking
advantage of the presence of accessory channel subunits in addition to
targeting channels restricted to a certain tissue type.
| |
Footnotes |
|---|
Received December 13, 1999; Accepted February 28, 2000
This work was supported by Grants HL20558, HL28958, and NS29755 from the National Institutes of Health, and by a postdoctoral fellowship to H.-S. W. from the American Heart Association, Heritage Affiliate.
Send reprint requests to: Dr. Hong-Sheng Wang, Department of Physiology and Biophysics, State University of New York, Stony Brook, NY 11794-8661. E-mail: hswang{at}physiology.pnb.sunysb.edu
| |
Abbreviations |
|---|
IKs, slowly activating cardiac delayed rectifier; G, conductance; Gmax, maximum conductance.
| |
References |
|---|
|
|
|---|
channel blockers on the Kv4.3 and Kv4.2 K+ channels: Implication for the study of the Ito2 current.
Circ Res
81:
711-718This article has been cited by other articles:
![]() |
Z. Gao, Q. Xiong, H. Sun, and M. Li Desensitization of Chemical Activation by Auxiliary Subunits: CONVERGENCE OF MOLECULAR DETERMINANTS CRITICAL FOR AUGMENTING KCNQ1 POTASSIUM CHANNELS J. Biol. Chem., August 15, 2008; 283(33): 22649 - 22658. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. C. L. Bett and R. L. Rasmusson Modification of K+ channel-drug interactions by ancillary subunits J. Physiol., February 15, 2008; 586(4): 929 - 950. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Wladyka, B. Feng, P. A. Glazebrook, J. H. Schild, and D. L. Kunze The KCNQ/M-current modulates arterial baroreceptor function at the sensory terminal in rats J. Physiol., February 1, 2008; 586(3): 795 - 802. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. L. vanTol, S. Missan, J. Crack, S. Moser, W. H. Baldridge, P. Linsdell, and E. A. Cowley Contribution of KCNQ1 to the regulatory volume decrease in the human mammary epithelial cell line MCF-7 Am J Physiol Cell Physiol, September 1, 2007; 293(3): C1010 - C1019. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, S. Y. Um, and T. V. Mcdonald Voltage-Gated Potassium Channels: Regulation by Accessory Subunits Neuroscientist, June 1, 2006; 12(3): 199 - 210. [Abstract] [PDF] |
||||
![]() |
S. Piccinin, A. D. Randall, and J. T. Brown KCNQ/Kv7 Channel Regulation of Hippocampal Gamma-Frequency Firing in the Absence of Synaptic Transmission J Neurophysiol, May 1, 2006; 95(5): 3105 - 3112. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. G. Korsgaard, B. P. Hartz, W. D. Brown, P. K. Ahring, D. Strobaek, and N. R. Mirza Anxiolytic Effects of Maxipost (BMS-204352) and Retigabine via Activation of Neuronal Kv7 Channels J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 282 - 292. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. W. G. Lambrecht, I. Yakubov, D. Scott, and G. Sachs Identification of the K efflux channel coupled to the gastric H-K-ATPase during acid secretion Physiol Genomics, March 21, 2005; 21(1): 81 - 91. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tamargo, R. Caballero, R. Gomez, C. Valenzuela, and E. Delpon Pharmacology of cardiac potassium channels Cardiovasc Res, April 1, 2004; 62(1): 9 - 33. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Catacuzzeno, B. Fioretti, and F. Franciolini Voltage-Gated Outward K Currents in Frog Saccular Hair Cells J Neurophysiol, December 1, 2003; 90(6): 3688 - 3701. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. F. Melman, A. Krumerman, and T. V. McDonald A Single Transmembrane Site in the KCNE-encoded Proteins Controls the Specificity of KvLQT1 Channel Gating J. Biol. Chem., July 5, 2002; 277(28): 25187 - 25194. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Xia, P. A. Lampe, M. Deshmukh, A. Yang, B. S. Brown, S. M. Rothman, E. M. Johnson Jr, and S. P. Yu Multiple Channel Interactions Explain the Protection of Sympathetic Neurons from Apoptosis Induced by Nerve Growth Factor Deprivation J. Neurosci., January 1, 2002; 22(1): 114 - 122. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Szkotak, A. M. L. Ng, J. Sawicka, S. A. Baldwin, S. F. P. Man, C. E. Cass, J. D. Young, and M. Duszyk Regulation of K+ current in human airway epithelial cells by exogenous and autocrine adenosine Am J Physiol Cell Physiol, December 1, 2001; 281(6): C1991 - C2002. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. MacVinish, Y. Guo, A.K. Dixon, R. D. Murrell-Lagnado, and A. W. Cuthbert XE991 Reveals Differences in K+ Channels Regulating Chloride Secretion in Murine Airway and Colonic Epithelium Mol. Pharmacol., October 1, 2001; 60(4): 753 - 760. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Rennie, T. Weng, and M. J. Correia Effects of KCNQ channel blockers on K+ currents in vestibular hair cells Am J Physiol Cell Physiol, March 1, 2001; 280(3): C473 - C480. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-C. Shieh, M. Coghlan, J. P. Sullivan, and M. Gopalakrishnan Potassium Channels: Molecular Defects, Diseases, and Therapeutic Opportunities Pharmacol. Rev., December 1, 2000; 52(4): 557 - 594. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||